Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr Ashleys Limited.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
These two companies have agreed to a reverse merger that will see Dr Ashleys Limited acquire Impact BioMedical, with the combined company trading under the Dr Ashleys Limited name. The Dr Ashleys management team will lead the combined company and will also create a new Board of Directors.
Dr. Kanans Visvanats, director of Dr. Ashleys Limited, said, “By integrating Impact Biomedical’s impressive IP portfolio into our R&D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health.”
IBO Stock Movement Today
IBO Stock was up 198.26% on Monday following news of its Dr. Ashleys Limited merger. That’s a positive change from its 75.03% drop year-to-date and 84.46% 12-month fall. Today’s news has seen more than 103 million shares of IBO stock traded, compared to a three-month daily average of about 390,000 units.
